Bionor Pharma strengthens its IP-platform in the US

Oslo, 20.05.2011 - Bionor Pharma ASA has today received confirmation of submission of patent applications in the US for its platform technologies.

Read more about Bionor Pharma strengthens its IP-platform in the US

Expert-reviews on universal influenza vaccine

Oslo, 25.05.2011 - Interview with CSO Maja Sommerfelt regarding universal flu vaccine

Read more about Expert-reviews on universal influenza vaccine

NMA (SLV) approve testing of Vacc-4x using a nasal administration system

Oslo, 16.06.2011 - Oslo University Hospital has received approval to test Bionor Pharma's HIV-vaccine, Vacc-4x, using a nasal administration system

Read more about NMA (SLV) approve testing of Vacc-4x using a nasal administration system

Vacc-4x phase IIB study accepted as a poster at the IAS conference

Oslo, 21.06.2011 - An abstract of Bionor Pharma's Vacc-4x phase IIB study has been accepted as poster at the IAS conference in Rome 17-20 July 2011.

Read more about Vacc-4x phase IIB study accepted as a poster at the IAS conference

Vacc-4x presented at AIDS Vaccine 2011 in Bangkok

(BANGKOK, Sep 12, 2011) Bionor Pharma presented Vacc-4x on "Global HIV Vaccine Enterprise" press conference at AIDS Vaccine 2011 in Bangkok

Read more about Vacc-4x presented at AIDS Vaccine 2011 in Bangkok

BIOtechNOW: International AIDS Conference Unveils Four New “Next Generation” Treatments for HIV

New data presented at the 2010 International AIDS Conference showed significant momentum for the emerging fields of therapeutic vaccines, anti-immune hyperactivation, and other immune based therapies for the treatment of HIV/AIDS.

Read more about BIOtechNOW: International AIDS Conference Unveils Four New “Next Generation” Treatments for HIV

Bionor Pharma develops universal influenza vaccine

Washington, 22.11.2011 - Bionor Pharma’s Universal Influenza Vaccine, Vacc-Flu, Targets Regions Shared by all Influenza A Strains; Reduces Serious Flu Symptoms by 25 Percent Over Standard Flu Vaccine in Animal Study.

Read more about Bionor Pharma develops universal influenza vaccine

Tester nesevaksine mot HIV

Oslo 02.12.2011 - På World AIDS day 1. desember 2011 skriver forskning.no om den pågående kliniske studien ved Oslo Universitetssykehus, hvor Bionor Pharma’s HIV vaksinekandidat Vacc-4x testes ut på HIV positive pasienter ved vaksinering i nesen.

Read more about Tester nesevaksine mot HIV

Bionor Pharma presenterer på influensakongress i USA

Oslo, 31.10.2011 - Bionor Pharma invitert til å presentere sin influensasatsing på influensakongress i USA.

Read more about Bionor Pharma presenterer på influensakongress i USA

Bionor Pharma ASA utvikler universell influensavaksine

Washington, 10.11.2011 - Bionor Pharma presenterer sin forebyggende influensavaksine Vacc-Flu på den viktigste årlige influensakongressen i USA (Arlington, Virginia).

Read more about Bionor Pharma ASA utvikler universell influensavaksine

Bionor Pharma presents on an Influenza congress in US

(Oslo, 31th October, 2011 - Bionor Pharma is invited to present its work on development on an Influenza vaccine on an influenza congress in USA

Read more about Bionor Pharma presents on an Influenza congress in US

Vacc-4x presenteres på "Global HIV Vaccine Enterprise" i Bangkok

Bangkok, 12.09.2011 - Bionor Pharma er invitert til å presentere Vacc-4x på pressekonferansen til "Global HIV Vaccine Enterprise" ved AIDS Vaccine 2011 i Bangkok.

Read more about Vacc-4x presenteres på "Global HIV Vaccine Enterprise" i Bangkok

Bionor Pharma presenterer på influensakongress i USA

Oslo, 31.10.2011 - Bionor Pharma invitert til å presentere sin influensasatsing på influensakongress i USA.

Read more about Bionor Pharma presenterer på influensakongress i USA

Vacc-4x results presented in Bangkok

Results from Phase IIB Placebo Controlled Study of Bionor’s Vacc-4x Show Excellent Safety Profile and Statistically Significant Viral Load Reduction in Patients with HIV who Suspend Antiretroviral Therapy.

Read more about Vacc-4x results presented in Bangkok

Vacc-4x presenteres på "Global HIV Vaccine Enterprise" i Bangkok

Bangkok, 12.09.2011 - Bionor Pharma er invitert til å presentere Vacc-4x på pressekonferansen til "Global HIV Vaccine Enterprise" ved AIDS Vaccine 2011 i Bangkok.

Read more about Vacc-4x presenteres på "Global HIV Vaccine Enterprise" i Bangkok

Vacc-4x phase IIB study accepted as a poster at AIDS conference in Bangkok

Oslo, 01.08.2011 - An abstract of Bionor Pharma's Vacc-4x phase IIB study has been accepted as a poster at the AIDS Vaccine 2011 conference in Bangkok 12-15 September.

Read more about Vacc-4x phase IIB study accepted as a poster at AIDS conference in Bangkok

Successful therapeutic vaccination with Vacc-4x

Successful therapeutic vaccination of HIV patients with Vacc-4x, Bionor Pharma’s peptide-based therapeutic vaccine for HIV-1 infection

Read more about Successful therapeutic vaccination with Vacc-4x

New clinical trial, HIV Vacc-4x in combination with Revlimid® (Lenalidomide)

Oslo - 25.08.11 - Bionor Pharma ASA Announces Exploratory Study of its Lead Therapeutic HIV-Vaccine Candidate Vacc-4x in Combination with Leading Cancer Drug

Read more about New clinical trial, HIV Vacc-4x in combination with Revlimid® (Lenalidomide)

New clinical trial, HIV Vacc-4x in combination with Revlimid® (Lenalidomide)

Oslo - 25.08.11 - Bionor Pharma ASA Announces Exploratory Study of its Lead Therapeutic HIV-Vaccine Candidate Vacc-4x in Combination with Leading Cancer Drug

Read more about New clinical trial, HIV Vacc-4x in combination with Revlimid® (Lenalidomide)

Ny klinisk studie, HIV Vacc-4x i kombinasjon med REVLIMID® (Lenalidomide)

Oslo - 25.08.2011 Bionor Pharma ASA vil studere effekten av Bionors terapeutiske HIV-vaksine Vacc-4x, i kombinasjon med REVLIMID® (Lenalidomide), hos pasienter med HIV.

Read more about Ny klinisk studie, HIV Vacc-4x i kombinasjon med REVLIMID® (Lenalidomide)

Ny klinisk studie, HIV Vacc-4x i kombinasjon med REVLIMID® (Lenalidomide)

Oslo - 25.08.2011 Bionor Pharma ASA vil studere effekten av Bionors terapeutiske HIV-vaksine Vacc-4x, i kombinasjon med REVLIMID® (Lenalidomide), hos pasienter med HIV.

Read more about Ny klinisk studie, HIV Vacc-4x i kombinasjon med REVLIMID® (Lenalidomide)

Vacc-4x phase IIB study accepted as a poster at AIDS conference in Bangkok

Oslo, 01.08.2011 - An abstract of Bionor Pharma's Vacc-4x phase IIB study has been accepted as a poster at the AIDS Vaccine 2011 conference in Bangkok 12-15 September.

Read more about Vacc-4x phase IIB study accepted as a poster at AIDS conference in Bangkok